Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
- PMID: 23754654
- DOI: 10.1002/bjs.9192
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes
Abstract
Background: The management of primary rectal cancer beyond total mesorectal excision planes (PRC-bTME) and recurrent rectal cancer (RRC) is challenging. There is global variation in standards and no guidelines exist. To achieve cure most patients require extended, multivisceral, exenterative surgery, beyond conventional total mesorectal excision planes. The aim of the Beyond TME Group was to achieve consensus on the definitions and principles of management, and to identify areas of research priority.
Methods: Delphi methodology was used to achieve consensus. The Group consisted of invited experts from surgery, radiology, oncology and pathology. The process included two international dedicated discussion conferences, formal feedback, three rounds of editing and two rounds of anonymized web-based voting. Consensus was achieved with more than 80 per cent agreement; less than 80 per cent agreement indicated low consensus. During conferences held in September 2011 and March 2012, open discussion took place on areas in which there is a low level of consensus.
Results: The final consensus document included 51 voted statements, making recommendations on ten key areas of PRC-bTME and RRC. Consensus agreement was achieved on the recommendations of 49 statements, with 34 achieving consensus in over 95 per cent. The lowest level of consensus obtained was 76 per cent. There was clear identification of the need for referral to a specialist multidisciplinary team for diagnosis, assessment and further management.
Conclusion: The consensus process has provided guidance for the management of patients with PRC-bTME or RRC, taking into account global variations in surgical techniques and technology. It has further identified areas of research priority.
Similar articles
-
Benchmarking trial between France and Australia comparing management of primary rectal cancer beyond TME and locally recurrent rectal cancer (PelviCare Trial): rationale and design.BMC Cancer. 2016 Apr 4;16:262. doi: 10.1186/s12885-016-2286-1. BMC Cancer. 2016. PMID: 27044252 Free PMC article. Clinical Trial.
-
Consensus statement on the multidisciplinary management of patients with recurrent and primary rectal cancer beyond total mesorectal excision planes.Br J Surg. 2013 Jul;100(8):E1-33. doi: 10.1002/bjs.9192_1. Br J Surg. 2013. PMID: 23901427
-
Techniques and Outcome of Surgery for Locally Advanced and Local Recurrent Rectal Cancer.Clin Oncol (R Coll Radiol). 2016 Feb;28(2):103-115. doi: 10.1016/j.clon.2015.11.006. Epub 2015 Dec 9. Clin Oncol (R Coll Radiol). 2016. PMID: 26683258 Review.
-
[Chinese expert consensus on the pelvic exenteration for primary rectal cancer beyond total mesorectal excision planes and locally recurrent rectal cancer (2023 edition)].Zhonghua Wei Chang Wai Ke Za Zhi. 2023 Jan 25;26(1):16-26. doi: 10.3760/cma.j.cn441530-20221114-00467. Zhonghua Wei Chang Wai Ke Za Zhi. 2023. PMID: 36649995 Chinese.
-
EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe.Eur J Cancer. 2013 Sep;49(13):2784-90. doi: 10.1016/j.ejca.2013.04.032. Epub 2013 Jun 14. Eur J Cancer. 2013. PMID: 23769991
Cited by
-
Benchmarking trial between France and Australia comparing management of primary rectal cancer beyond TME and locally recurrent rectal cancer (PelviCare Trial): rationale and design.BMC Cancer. 2016 Apr 4;16:262. doi: 10.1186/s12885-016-2286-1. BMC Cancer. 2016. PMID: 27044252 Free PMC article. Clinical Trial.
-
Utility of circulating tumour DNA for prognosis and prediction of therapeutic effect in locally recurrent rectal cancer: study protocol for a multi-institutional, prospective observational study (JCOG1801A1, CAP-LR study).BMJ Open. 2023 Aug 16;13(8):e073217. doi: 10.1136/bmjopen-2023-073217. BMJ Open. 2023. PMID: 37586869 Free PMC article.
-
Excluding external iliac node irradiation during neoadjuvant radiotherapy decreases lower intestinal toxicity without compromising efficacy in T4b rectal cancer patients with tumours involving the anterior structures.Discov Oncol. 2024 Mar 16;15(1):76. doi: 10.1007/s12672-024-00885-6. Discov Oncol. 2024. PMID: 38492016 Free PMC article.
-
Locally advanced rectal cancer: management challenges.Onco Targets Ther. 2016 Oct 13;9:6265-6272. doi: 10.2147/OTT.S100806. eCollection 2016. Onco Targets Ther. 2016. PMID: 27785074 Free PMC article. Review.
-
Pelvic exenterations for primary rectal cancer: Analysis from a 10-year national prospective database.World J Gastroenterol. 2018 Dec 7;24(45):5144-5153. doi: 10.3748/wjg.v24.i45.5144. World J Gastroenterol. 2018. PMID: 30568391 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources